Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $50.60
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been assigned an average rating of “Buy” from the ten analysts that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price […]
More Stories
Western Asset Emerging Markets Debt Fund Inc. (EMD) To Go Ex-Dividend on September 23rd
Western Asset Emerging Markets Debt Fund Inc. (NYSE:EMD – Get Free Report) announced a monthly dividend on Tuesday, August 6th,...
Knowles (NYSE:KN) Updates Q3 2024 Earnings Guidance
Knowles (NYSE:KN – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The...
Fidelity Disruptive Finance ETF (FDFF) To Go Ex-Dividend on September 20th
Fidelity Disruptive Finance ETF (NASDAQ:FDFF – Get Free Report) declared a quarterly dividend on Thursday, September 19th, NASDAQ reports. Shareholders...
Rezolute (NASDAQ:RZLT) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS
Rezolute (NASDAQ:RZLT – Get Free Report) posted its earnings results on Thursday. The company reported ($0.44) earnings per share (EPS)...
MillerKnoll (NASDAQ:MLKN) Issues FY25 Earnings Guidance
MillerKnoll (NASDAQ:MLKN – Get Free Report) issued an update on its FY25 earnings guidance on Thursday morning. The company provided...
Lennar (NYSE:LEN) Updates Q4 2024 Earnings Guidance
Lennar (NYSE:LEN – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Friday morning. The...